Fewer than 1 in 3 children with hepatitis C (HCV) see a clinician for care, and fewer than 1 in 8 receive treatment.

These scientists sought to answer a simple question. They ended up stumbling upon a discovery that could pave the way for a ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Novavax is working with the FDA to meet additional requirements and hopes to secure full approval as soon as possible.

ASTANA – Kazakhstan has launched European Immunization Week (EIW), taking place from April 27 to May 3 under the theme: ...

Primary hepatitis C virus (HCV) care cascade outcomes are low among children with HCV, with racial and ethnic disparities ...

Dr. Esther Park, whose license was restricted to office-based gynecology in December, will effectively stop practising ...

PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

Empathetic and persistent communication is key when it comes to talking to parents who are reluctant to vaccinate their child ...

Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by ...